A local sustained-release drug delivery system, or depot, for intra-articular injection offers the opportunity to release a therapeutic agent directly to the joint with limited need for reinjection. A successful system would provide more consistent efficacy and minimize systemic side effects. In this paper, we explore the potential use of diclofenac, a non-steroidal anti-inflammatory drug, for use in a polymer-conjugate depot system. During the course of our exploration it was determined that "conventional ester" conjugates of diclofenac were not appropriate as upon incubation in buffer (pH 7.4) or in bovine synovial fluid, a considerable amount of undesired diclofenac-lactam was released. Thus we developed a novel linker system for diclofenac in order to minimize the production of the lactam. This new linker enables a diclofenac conjugate system with tunable release rates and minimizes the production of undesired lactam side-products.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2020.119519DOI Listing

Publication Analysis

Top Keywords

conjugate system
8
system
6
novel diclofenac-hydrogel
4
diclofenac-hydrogel conjugate
4
system intraarticular
4
intraarticular sustained
4
sustained release
4
release development
4
development 2-pyridylamino-substituted
4
2-pyridylamino-substituted 1-phenylethanol
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!